Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative

Michael S. Simon & Jennifer L. Beebe‐Dimmer et al. · 2020-11-05

Background

Cardiometabolic abnormalities are a leading cause of death among women, including women with cancer.

Methods

This study examined the association between prediagnosis cardiovascular health and total and cause‐specific mortality among 12,076 postmenopausal women who developed local‐ or regional‐stage invasive cancer in the Women's Health Initiative (WHI). Cardiovascular risk factors included waist circumference, hypertension, high cholesterol, and type 2 diabetes. Obesity‐related cancers included breast cancer, colorectal cancer, endometrial cancer, kidney cancer, pancreatic cancer, ovarian cancer, stomach cancer, liver cancer, and non‐Hodgkin lymphoma. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) adjusted for important predictors of survival.

Results

After a median follow‐up of 10.0 years from the date of the cancer diagnosis, there were 3607 total deaths, with 1546 (43%) due to cancer. Most participants (62.9%) had 1 or 2 cardiometabolic risk factors, and 8.1% had 3 or 4. In adjusted models, women with 3 to 4 risk factors (vs none) had a higher risk of all‐cause mortality (HR, 1.99; 95% CI, 1.73‐2.30), death due to cardiovascular disease (CVD) (HR, 4.01; 95% CI, 2.88‐5.57), cancer‐specific mortality (HR, 1.37; 95% CI, 1.1‐1.72), and other‐cause mortality (HR, 2.14; 95% CI, 1.70‐2.69). A higher waist circumference was associated with greater all‐cause mortality (HR, 1.17; 95% CI, 1.06‐1.30) and cancer‐specific mortality (HR, 1.22; 95% CI, 1.04‐1.42).

Conclusions

Among postmenopausal women diagnosed with cancer in the WHI, cardiometabolic risk factors before the cancer diagnosis were associated with greater all‐cause, CVD, cancer‐specific, and other‐cause mortality. These results raise hypotheses regarding potential clinical intervention strategies targeting cardiometabolic abnormalities that require future prospective studies for confirmation.

Lay Summary

  • This study uses information from the Women's Health Initiative (WHI) to find out whether cardiac risk factors are related to a greater risk of dying among older women with cancer. The WHI is the largest study of medical problems faced by older women in this country.

  • The results show that women who have 3 or 4 risk factors are more likely to die of any cause, heart disease, or cancer in comparison with women with no risk factors.

  • It is concluded that interventions to help to lower the burden of cardiac risk factors can have an important impact on survivorship among women with cancer.

Journal
Cancer
Funding
Genetic and Biochemical Predictors of Type 2 DM in WomenWomen's Health Initiative Cancer Survivor CohortNHLBI NIH HHS Grant 32100-2Development of stretchable optical sensors for measurement of penile hemodynamicsCOORDINATING CENTER FOR WOMENS HEALTH INITIATIVE-260922110-268022110Regulation of chromosome inheritance and integrityWomen's Health Initiative Clinical Coordinating CenterLife and Longevity After Cancer (LILAC): The Women's Health Initiative Cancer Survivor CohortTherapeutic applications of CD4+ T cells specific for oncogenic driver mutationsInvestigating the role of genes, maternal exposures, and interactions on orofacial cleftsWomen's Health Initiative Memory Study (WHIMS)A Culturally-Tailored Weight Loss ProgramNHLBI NIH HHS Grant 32108-9Telomere and its bio-regulators as predictors for clinical diabetes in womenFriend-based Intervention to Reduce Alcohol-Involved Sexual Assault RiskNHLBI NIH HHS Grant 32105-6CANCER CENTER SUPPORT GRANTRole of the Epitranscriptome in CancerSensing local nano-environment with coherent Raman microspectroscopyWomen's Health Initiative Clinical Coordinating CenterNational Heart Lung and Blood Institute Grant 24152National Heart, Lung, and Blood Institute Grant 32100‐2National Heart, Lung, and Blood Institute Grant 32105‐6National Heart, Lung, and Blood Institute Grant 32108‐9National Heart, Lung, and Blood Institute Grant 32111‐13National Heart Lung and Blood Institute Grant 32115National Heart, Lung, and Blood Institute Grant 32118‐32119National Heart Lung and Blood Institute Grant 32122National Heart, Lung, and Blood Institute Grant 42107‐26National Heart, Lung, and Blood Institute Grant 42129‐32National Heart Lung and Blood Institute Grant 44221CANCER CENTER SUPPORT GRANT

NIDDK NIH HHS

R01 DK062290

NCI NIH HHS

UM1 CA173642

NHLBI NIH HHS

42129-32

WHI NIH HHS

N01 WH022110

NHLBI NIH HHS

32111-13

NHLBI NIH HHS

N01WH22110

NCI NIH HHS

U01 CA173642

NCI NIH HHS

R21 CA100720

NIDDK NIH HHS

R21 DK084452

NHLBI NIH HHS

32118-32119

NCI NIH HHS

P30 CA022453

NHLBI NIH HHS

42107-26

National Heart, Lung, and Blood Institute

N01WH22110

National Cancer Institute

P30CA022453